Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Cardinal Health Inc    CAH

News SummaryMost relevantAll newsSector news 

Cardinal Health to Buy Medical-Supplies Provider AssuraMed for $2.07 Billion

02/14/2013 | 08:08am US/Eastern
   By Melodie Warner 

Cardinal Health Inc. (>> Cardinal Health, Inc.) agreed to acquire closely held medical-supplies provider AssuraMed for $2.07 billion as the drug wholesaler looks to diversify its offerings.

AssuraMed currently serves more than one million patients nationally with more than 30,000 products. The company bought Invacare Corp.'s (>> Invacare Corporation) domestic medical supplies business for $150 million last month. Including that business, Cardinal Heath said AssuraMed had 2012 revenue of $1 billion.

After the transaction is complete, Cardinal Health will supply ostomy, diabetes, insulin therapy, urological, wound care and incontinence products to the home-healthcare market.

"This is a platform opportunity for Cardinal Health products and services which will be increasingly important as the delivery of care migrates to more cost-effective settings," said Chairman and Chief Executive George Barrett.

Cardinal Health expects AssuraMed to add two cents to three cents a share to its fiscal 2013 adjusted earnings, assuming the deal closes by early April.

The company also estimates its will boost fiscal 2014 adjusted earnings by at least 18 cents a share.

Cardinal has previously disclosed the loss of its contract with pharmacy-benefits manager Express Scripts Holding Co. (>> Express Scripts Holding Co) to rival AmerisourceBergen Corp. (>> AmerisourceBergen Corp.). Two of Cardinal's huge drug-distribution customers, Walgreen Co. (>> Walgreen Company) and CVS Caremark Corp. (>> CVS Caremark Corporation), have contracts set to end this summer.

The company earlier this month reported its fiscal second-quarter earnings rose 16% as improved margins helped to offset weaker revenue at its pharmaceutical division, which was caused partly by generic-drug introductions.

Shares closed Wednesday at $45.44 and were inactive premarket. The stock has risen 8% over the past year.

Write to Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

React to this article
11/19 CARDINAL HEALTH : Strong Results Reported for the Cordis INCRAFT® AAA Stent Graf..
11/18 CARDINAL HEALTH : Vigilant Biosciences Selects Cardinal Health as Global Third P..
11/16 THERMO FISHER SCIENTIFIC : The Health Industry Distributors Association - Briefi..
11/13 THERMO FISHER SCIENTIFIC : The Health Industry Distributors Association - Briefi..
11/09 CARDINAL HEALTH : Other Events (form 8-K/A)
11/06 CARDINAL HEALTH : Pharmacy Expert Shares Insights on New Reimbursement Programs ..
11/04 CARDINAL HEALTH : Announces Quarterly Dividend and Preliminary Shareholder Votin..
11/03 CARDINAL HEALTH : Management's Discussion and Analysis of Financial Condition an..
11/02DJCARDINAL HEALTH : Raises Outlook, Profit Rises 44%
11/02DJCARDINAL HEALTH : Raises Outlook, Profit Rises 44%
News chart
Full-screen chart
Income Statement Evolution
More Financials